創薬技術市場：薬剤タイプ、アッセイ技術、技術プラットフォーム、用途、エンドユーザー別-2025～2030年世界予測

創薬技術市場は、2024年には635億米ドルとなり、2025年にはCAGR 10.67%で701億9,000万米ドルに成長し、2030年には1,167億1,000万米ドルに達すると予測されています。

創薬は、先進的技術、革新的な手法、学際的な協力関係によって織り成される複雑なタペストリーへと進化してきました。この産業は過去10年間、画期的な技術革新とデジタルの進歩を活用して、新規治療の同定と開発の複雑さに対処するという、変革的な変化を目の当たりにしてきました。このダイナミックな環境において、伝統的手法は計算ツールや高性能プラットフォームで補強され、研究者は対象の同定から前臨床評価までのプロセスを合理化できるようになりました。精度と効率の絶え間ない追求は、方法論を再定義しただけでなく、よりデータ主導型の医薬品開発への道を開いた。

本エグゼクティブサマリーでは、最先端の動向、戦略的セグメンテーション、地域の力学、市場を形成する主要企業について概説します。技術の進歩と市場の需要の相互作用を捉え、新たな動向が競合情勢をどのように煽るかを考察しています。創薬の様々なセグメントにわたる変化の層を紐解いていくと、イノベーションが進歩の中心にあることが明らかになります。学術機関から大手製薬企業まで、利害関係者は現在、この進化の恩恵を受ける立場にあり、伝統的境界線が統合された技術対応のソリューションに取って代わられています。

精密医療と個別化治療がますます顕著になる時代において、こうした変革の背後にある原動力を理解することは極めて重要です。この採用では、創薬の成果を再定義する戦略的要素を包括的に検討し、これらの機会を活用することを目指す意思決定者に明確なロードマップを記載しています。

現代の創薬エコシステムを形成する変革的シフト

ここ数年、創薬エコシステムには大きな変革が起きています。これらの変化は、単なる漸進的な改善ではなく、研究開発のあり方を根本的に見直すものです。技術と生物学の融合は、創薬の効率と精度を劇的に向上させる革新的な手法に拍車をかけた。

最も大きな変革のひとつは、先進的計算モデルの統合です。最新の計算モデリングプラットフォームにより、研究者は分子間相互作用を驚くほど正確にシミュレートできるようになりました。この機能により、有望な薬剤候補を迅速に同定することができ、実験的検証に伴う時間とコストを削減することができます。ハイ・スループット・スクリーニング技術は、膨大な化合物ライブラリーを素早くふるいにかけることで、こうした計算科学的努力を補完し、リード化合物探索プロセスを加速しています。

ナノテクノロジーと構造による設計もまた、新規治療の概念化に革命をもたらしています。これらのアプローチにより、科学者たちは、標的外作用を抑えつつ、特異性と効力を強化した分子を設計することができます。薬剤設計に詳細な構造情報を取り入れることで、より情報に基づいたアプローチが容易になり、複雑な生物学的システムを調節できる選択性の高い化合物の開発につながります。

さらに、薬理ゲノミクスと個別化医療の進歩は、標的治療の時代を到来させました。このパラダイムシフトは、患者固有の要因を優先し、個人の遺伝的体質に合わせた治療を保証するものです。その結果、治療の可能性が最大限に引き出される一方で、副作用は最小限に抑えられます。デジタルバイオロジーの進歩は、自動化やデータ分析の増加とともに、創薬の予測力をさらに高めています。

アッセイ技術の信頼性も高まり、洗練された結合アッセイ、生化学的手法、細胞ベースのアッセイ、レポーター遺伝子アッセイによって、化合物の挙動に関する多次元的な洞察が得られるようになりました。これらの強固な方法論は、化合物が意図された生物学的標的と相互作用するだけでなく、望ましい薬剤動態学的と薬力学的特性を示すことを確実にする、バリデーションの重要なレイヤーを記載しています。

産業が急速に変化する情勢に適応し続ける中、これらの革新的な技術の統合は、産業の標準と期待を再定義しつつあります。医薬品開発における利害関係者は、多様な技術プラットフォーム間の協力と相互運用性が成功の鍵となる、全体的な視点を採用するようになってきています。この進化する枠組みは、現代の創薬が多用途であることの証であり、21世紀の医療イノベーションの要として位置づけられています。

創薬市場の主要セグメンテーション洞察

創薬市場を詳細に分析することで、産業の運営フレームワークの微妙な理解を提供する構造的なセグメンテーションが明らかになります。その基礎となる薬剤タイプ別セグメンテーションでは、生物製剤と低分子製剤が区別され、それぞれに治療上の利点と製造上の課題があります。生物に由来する生物製剤は、複雑な疾患を対象に優れた効果を発揮します。対照的に、低分子医薬品は、その確立された製造プロセスと費用対効果により、伝統的に製薬産業の主力医薬品として機能してきました。

市場セグメンテーションがさらに細分化されるのは、アッセイ技術の領域です。市場は、結合アッセイ、生化学的アッセイ、細胞ベースのアッセイ、レポーター遺伝子アッセイを通じて綿密に調査されます。これらの技術は、基本的な相互作用の確認から詳細な機能分析まで、様々なレベルの知見を記載しています。これらの手法を創薬プロセスに組み込むことで、リード化合物の薬理学的特性が総合的に評価されます。

アッセイ技術に加えて、技術プラットフォームによるセグメンテーションも、市場分析の極めて重要な側面として浮上してきました。計算モデリング、高性能スクリーニング、ナノテクノロジー、ファーマコゲノミクス、構造ベースデザインは、このセグメントにおける技術革新の重要な原動力です。計算モデリングは初期段階の研究を加速し、高性能スクリーニングは候補化合物を効率的に絞り込みます。ナノテクノロジーは分子スケールの精度を導入し、構造ベースデザインはタンパク質とリガンドの三次元コンフォメーションを活用してターゲティングを強化します。一方、ファーマコゲノミクスは、治療パラダイムを個人の遺伝子プロファイルに合わせることで、個別化医療への動きを体現しています。

さらに、創薬における用途別セグメンテーションは、異なる治療段階と開発段階に沿って市場を分割します。包括的なアプローチでは、リード化合物の探索と同時にバイオマーカーの探索が考慮され、前臨床と臨床開発も含まれます。さらに、標的の同定とバリデーション、毒性検査にも及びます。このような多角的なセグメンテーションにより、医薬品開発パイプラインの各段階が、全体的な成功率に潜在的な影響を与えるかどうかを精査することができます。

最後に、エンドユーザー別セグメンテーションでは、市場を学術機関、バイオテクノロジー企業、製薬企業に分類しています。この区分は、創薬が多様なエコシステムで展開されていることを浮き彫りにしています。学術機関は基礎研究と初期段階の発見を通じて貢献し、バイオテクノロジー企業は斬新なアイデアと機敏な戦略でイノベーションを推進し、製薬会社は大規模な事業と臨床の専門知識を活用して医薬品を市場に送り出します。これらのセグメンテーションの視点を相互に関連付けることで、分析フレームワークは創薬技術の現状と将来の方向性の両方を包括的に示しています。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 慢性疾患の増加と満たされていない医療ニーズ
    • 慢性疾患と感染症の治療における低分子薬と生物製剤の使用増加
    • 世界中のCDMOによる創薬技術の急速な採用
  • 抑制要因
    • 高い間接費と高い故障率への懸念
  • 機会
    • 最先端の計算モデリングと分子シミュレーションプラットフォームの開発
    • ゲノミクス調査と高性能スクリーニング技術の進歩
  • 課題
    • 複雑な規制要件と長い承認プロセス
• 市場セグメンテーション分析
  • 薬剤タイプ：自己免疫疾患とがんの治療における生物製剤の重要性の高まり
  • エンドユーザー：学術機関における創薬技術の採用拡大
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 創薬技術市場：薬剤タイプ別

• イントロダクション
• 生物製剤
• 低分子医薬品

第7章 創薬技術市場：アッセイ技術別

• イントロダクション
• 結合アッセイ
• 生化学アッセイ
• 細胞ベースアッセイ
• レポーター遺伝子アッセイ

第8章 創薬技術市場：技術プラットフォーム

• イントロダクション
• 計算モデリング
• 高性能スクリーニング
• ナノテクノロジー
• 薬理ゲノミクス
• 構造ベースの設計

第9章 創薬技術市場：用途別

• イントロダクション
• バイオマーカーの発見
• 候補発見
• 前臨床と臨床開発
• 対象の特定と検証
• 毒性検査

第10章 創薬技術市場：エンドユーザー別

• イントロダクション
• 学術機関
• バイオテクノロジー企業
• 製薬会社

第11章 南北アメリカの創薬技術市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋の創薬技術市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの創薬技術市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析、2024年
• FPNVポジショニングマトリックス、2024年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories, Inc.
• Amgen Inc.
• AstraZeneca PLC
• Bayer Healthcare AG
• Bio-Rad Laboratories, Inc.
• bioMerieux SA
• Bristol-Myers Squibb Company
• Covaris, LLC
• Curia Global, Inc.
• Elucidata Corporation
• Eurofins Advinus Private Limited
• Evotec SE
• F. Hoffmann-La Roche Ltd.
• GE Healthcare Ltd.
• Gilead Sciences, Inc.
• Horiba, Ltd.
• Illumina, Inc.
• IQVIA Inc.
• Luminex Corporation by DiaSorin Group
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• PIRAMAL PHARMA LIMITED
• Randox Laboratories Ltd.
• Revolution Medicines, Inc.
• Sanofi S.A.
• Sygnature Discovery Limited
• Syngene International Limited
• Thermo FIsher Scientific Inc.
• VWR International LLC
• WuXi AppTec Co., Ltd.

LIST OF FIGURES

• FIGURE 1. DRUG DISCOVERY TECHNOLOGIES MARKET MULTI-CURRENCY
• FIGURE 2. DRUG DISCOVERY TECHNOLOGIES MARKET MULTI-LANGUAGE
• FIGURE 3. DRUG DISCOVERY TECHNOLOGIES MARKET RESEARCH PROCESS
• FIGURE 4. DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2024 VS 2030
• FIGURE 5. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
• FIGURE 9. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2024 VS 2030 (%)
• FIGURE 11. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2024 VS 2030 (%)
• FIGURE 13. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
• FIGURE 15. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
• FIGURE 17. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 19. AMERICAS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 21. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 26. DRUG DISCOVERY TECHNOLOGIES MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 27. DRUG DISCOVERY TECHNOLOGIES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. DRUG DISCOVERY TECHNOLOGIES MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. DRUG DISCOVERY TECHNOLOGIES MARKET DYNAMICS
• TABLE 7. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BIOLOGIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY SMALL-MOLECULE DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BINDING ASSAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BIOCHEMICAL ASSAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY CELL BASED ASSAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY REPORTER GENE ASSAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COMPUTATIONAL MODELING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY HIGH THROUGHPUT SCREENING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY NANOTECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY PHARMACOGENOMICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY STRUCTURE BASED DESIGN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY LEAD DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY PRECLINICAL & CLINICAL DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TOXICOLOGY TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY BIOTECHNOLOGY FIRMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 33. AMERICAS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 38. ARGENTINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 39. ARGENTINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 40. ARGENTINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 43. BRAZIL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 44. BRAZIL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 45. BRAZIL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 46. BRAZIL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 47. CANADA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 48. CANADA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 49. CANADA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 50. CANADA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 51. CANADA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 53. MEXICO DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 54. MEXICO DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 55. MEXICO DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 56. MEXICO DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 59. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 60. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 61. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 62. UNITED STATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 65. ASIA-PACIFIC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 66. ASIA-PACIFIC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 67. ASIA-PACIFIC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 68. ASIA-PACIFIC DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 70. AUSTRALIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 71. AUSTRALIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 72. AUSTRALIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 73. AUSTRALIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 74. CHINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 75. CHINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 76. CHINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 77. CHINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 78. CHINA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 79. INDIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 80. INDIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 81. INDIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 82. INDIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 83. INDIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 85. INDONESIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 86. INDONESIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 87. INDONESIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 88. INDONESIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 90. JAPAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 91. JAPAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 92. JAPAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 93. JAPAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 95. MALAYSIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 96. MALAYSIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 97. MALAYSIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 98. MALAYSIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 100. PHILIPPINES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 101. PHILIPPINES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 102. PHILIPPINES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 103. PHILIPPINES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 105. SINGAPORE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 106. SINGAPORE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 107. SINGAPORE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 108. SINGAPORE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 110. SOUTH KOREA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 111. SOUTH KOREA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 112. SOUTH KOREA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. SOUTH KOREA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 115. TAIWAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 116. TAIWAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 117. TAIWAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 118. TAIWAN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 120. THAILAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 121. THAILAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 122. THAILAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 123. THAILAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 125. VIETNAM DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 126. VIETNAM DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 127. VIETNAM DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 128. VIETNAM DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 131. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 132. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 133. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 134. EUROPE, MIDDLE EAST & AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 136. DENMARK DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 137. DENMARK DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 138. DENMARK DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 139. DENMARK DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 141. EGYPT DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 142. EGYPT DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 143. EGYPT DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 144. EGYPT DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 146. FINLAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 147. FINLAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 148. FINLAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 149. FINLAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 151. FRANCE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 152. FRANCE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 153. FRANCE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 154. FRANCE DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 156. GERMANY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 157. GERMANY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 158. GERMANY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 159. GERMANY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 161. ISRAEL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 162. ISRAEL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 163. ISRAEL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 164. ISRAEL DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 165. ITALY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 166. ITALY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 167. ITALY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 168. ITALY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 169. ITALY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 171. NETHERLANDS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 172. NETHERLANDS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 173. NETHERLANDS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 174. NETHERLANDS DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 176. NIGERIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 177. NIGERIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 178. NIGERIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 179. NIGERIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 181. NORWAY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 182. NORWAY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 183. NORWAY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 184. NORWAY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 185. POLAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 186. POLAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 187. POLAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 188. POLAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 189. POLAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 190. QATAR DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 191. QATAR DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 192. QATAR DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 193. QATAR DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 194. QATAR DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 196. RUSSIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 197. RUSSIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 198. RUSSIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 199. RUSSIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 201. SAUDI ARABIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 202. SAUDI ARABIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 203. SAUDI ARABIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 204. SAUDI ARABIA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 208. SOUTH AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 209. SOUTH AFRICA DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 211. SPAIN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 212. SPAIN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 213. SPAIN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 214. SPAIN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 216. SWEDEN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 217. SWEDEN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 218. SWEDEN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 219. SWEDEN DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 221. SWITZERLAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 222. SWITZERLAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 223. SWITZERLAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 224. SWITZERLAND DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 226. TURKEY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 227. TURKEY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 228. TURKEY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 229. TURKEY DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 231. UNITED ARAB EMIRATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 232. UNITED ARAB EMIRATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 233. UNITED ARAB EMIRATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 234. UNITED ARAB EMIRATES DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 236. UNITED KINGDOM DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY ASSAY TECHNIQUES, 2018-2030 (USD MILLION)
• TABLE 237. UNITED KINGDOM DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY TECHNOLOGY PLATFORMS, 2018-2030 (USD MILLION)
• TABLE 238. UNITED KINGDOM DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 239. UNITED KINGDOM DRUG DISCOVERY TECHNOLOGIES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 240. DRUG DISCOVERY TECHNOLOGIES MARKET SHARE, BY KEY PLAYER, 2024
• TABLE 241. DRUG DISCOVERY TECHNOLOGIES MARKET, FPNV POSITIONING MATRIX, 2024

The Drug Discovery Technologies Market was valued at USD 63.50 billion in 2024 and is projected to grow to USD 70.19 billion in 2025, with a CAGR of 10.67%, reaching USD 116.71 billion by 2030.

Drug discovery has evolved into an intricate tapestry woven with advanced technologies, innovative techniques, and multidisciplinary collaboration. The industry has witnessed a transformative shift over the past decade, leveraging breakthrough innovations and digital advancements to address the complexities of identifying and developing new therapeutics. In this dynamic environment, traditional methods have been augmented with computational tools and high-throughput platforms, enabling researchers to streamline the process from target identification through preclinical evaluation. The relentless pursuit of precision and efficiency has not only redefined methodologies but also paved the way for a more data-driven approach to drug development.

This executive summary outlines the state-of-the-art trends, strategic segmentation, regional dynamics, and key players shaping the market. It captures the interplay between technological advances and market demands, offering insights into how emerging trends are fueling a competitive landscape. As we unravel the layers of change across various segments of drug discovery, it becomes evident that innovation is at the heart of progress. Stakeholders ranging from academic institutions to pharmaceutical giants are now positioned to benefit from this evolution, as traditional boundaries give way to integrated, technology-enabled solutions.

In an era where precision medicine and personalized therapies are becoming increasingly prominent, understanding the drivers behind these transformative shifts is crucial. This introduction sets the stage for a comprehensive exploration of the strategic elements that are redefining outcomes in drug discovery, providing a clear roadmap for decision-makers aiming to harness these opportunities.

Transformative Shifts Shaping the Modern Drug Discovery Ecosystem

Recent years have witnessed profound and transformative changes within the drug discovery ecosystem. These shifts are not merely incremental improvements but represent a fundamental rethinking of how research and development are conducted. The convergence of technology and biology has spurred innovative methodologies that dramatically increase the efficiency and accuracy of drug discovery.

One of the most significant transformations is the integration of advanced computational models. Modern computational modeling platforms enable researchers to simulate molecular interactions with remarkable precision. This capability allows for the rapid identification of promising drug candidates, reducing the time and cost associated with experimental validation. High throughput screening technologies now complement these computational efforts by quickly sifting through vast libraries of compounds, thereby accelerating the lead discovery process.

Nanotechnology and structure-based design are also revolutionizing the way novel therapeutics are conceptualized. These approaches empower scientists to design molecules with enhanced specificity and potency, while reducing off-target effects. Incorporating detailed structural information into drug design facilitates a more informed approach, leading to the development of highly selective compounds capable of modulating complex biological systems.

Moreover, advancements in pharmacogenomics and personalized medicine have ushered in an era of targeted therapies. This paradigm shift prioritizes patient-specific factors, ensuring that treatments are tailored to the individual's genetic makeup. As a result, the therapeutic potential is maximized while adverse effects are minimized. The advances in digital biology, along with increased automation and data analytics, have further enhanced the predictive power of drug discovery efforts.

The reliability of assay techniques has also grown, with refined binding assays, biochemical methods, cell based assays, and reporter gene assays now offering multidimensional insights into compound behavior. These robust methodologies provide a critical layer of validation, ensuring that compounds not only interact with their intended biological targets but also exhibit the desired pharmacokinetic and pharmacodynamic properties.

As the industry continues to adapt to a rapidly changing landscape, the integration of these innovative technologies is redefining industry standards and expectations. Stakeholders in drug development are increasingly adopting a holistic view, where collaboration and interoperability between diverse technological platforms are key drivers of success. This evolving framework is a testament to the versatility of modern drug discovery, positioning it as a cornerstone of medical innovation in the 21st century.

Key Segmentation Insights into the Drug Discovery Market

A detailed analysis of the drug discovery market reveals a structured segmentation that offers a nuanced understanding of the industry's operational framework. At its foundation, segmentation by drug type distinguishes between biologic drugs and small-molecule drugs, each presenting distinct therapeutic advantages and manufacturing challenges. Biologic drugs, which are derived from living organisms, have demonstrated superior efficacy in targeting complex diseases. In contrast, small-molecule drugs have traditionally served as the workhorses of the pharmaceutical industry due to their well-established manufacturing processes and cost-effectiveness.

Further refinement of market segmentation is observed in the realm of assay techniques. The market is meticulously studied through binding assays, biochemical assays, cell based assays, and reporter gene assays. These techniques provide varied levels of insight, from basic interaction confirmation to detailed functional analysis. Integrating these methods into the drug discovery process ensures that lead compounds are evaluated comprehensively for their pharmacological properties.

In addition to assay techniques, segmentation based on technology platforms has emerged as a pivotal aspect of market analysis. Computational modeling, high throughput screening, nanotechnology, pharmacogenomics, and structure based design are the critical drivers of innovation in this space. Each platform offers a unique advantage: computational modeling accelerates early-stage research, while high throughput screening efficiently narrows down candidate compounds. Nanotechnology introduces precision at a molecular scale, and structure based design leverages the three-dimensional conformation of proteins and ligands for enhanced targeting. Pharmacogenomics, meanwhile, embodies the move towards personalized medicine by aligning treatment paradigms with individual genetic profiles.

Moreover, the application-specific segmentation in drug discovery divides the market along different therapeutic and developmental stages. The comprehensive approach considers biomarker discovery alongside lead discovery, while also encompassing preclinical and clinical development. It further extends to target identification and validation, as well as toxicology testing. This multidimensional segmentation ensures that every phase of the drug development pipeline is scrutinized for its potential impact on overall success rates.

Finally, segmentation by end user categorizes the market into academic institutions, biotechnology firms, and pharmaceutical companies. This distinction highlights the diverse ecosystem in which drug discovery operates. Academic institutions contribute through fundamental research and early-stage discoveries, biotechnology firms drive innovation with novel ideas and nimble strategies, and pharmaceutical companies leverage large-scale operations and clinical expertise to bring drugs to market. By interlacing these segmentation perspectives, the analytical framework provides a comprehensive picture of both the current state and future directions of drug discovery technologies.

Based on Drug Type, market is studied across Biologic Drugs and Small-Molecule Drugs.

Based on Assay Techniques, market is studied across Binding Assays, Biochemical Assays, Cell Based Assays, and Reporter Gene Assays.

Based on Technology Platforms, market is studied across Computational Modeling, High Throughput Screening, Nanotechnology, Pharmacogenomics, and Structure Based Design.

Based on Application, market is studied across Biomarker Discovery, Lead Discovery, Preclinical & Clinical Development, Target Identification & Validation, and Toxicology Testing.

Based on End User, market is studied across Academic Institutions, Biotechnology Firms, and Pharmaceutical Companies.

Key Regional Insights Across Global Markets

The regional dynamics in the drug discovery market are as varied as they are significant, with distinct trends observed across major global territories. In the Americas, the market benefits from centralization of research institutions and a robust ecosystem of biotechnology companies and pharmaceutical corporations. The region is known for its high investment in R&D and rapid adoption of technological advancements. This focus is supported by a favorable regulatory environment that encourages innovation while ensuring patient safety. The sustained growth in the Americas is largely attributable to strong government incentives, extensive private funding, and a collaborative environment that marries academic research with industry-led initiatives.

Turning to the Europe, Middle East & Africa region, a blend of rich research heritage and emerging innovation hubs characterizes the landscape. Europe contributes significantly to drug discovery through its well-established infrastructure and rigorous regulatory standards, which foster high-quality research and development. The Middle East & Africa, while representing emerging markets, are increasingly becoming attractive due to their growing investments in healthcare infrastructure and strategic partnerships that aim to integrate global expertise with local talent. The cross-pollination of ideas between established research centers in Europe and the nascent but rapidly evolving markets in the Middle East & Africa creates a dynamic platform for breakthrough innovations and commercialization of novel therapeutics.

In the Asia-Pacific region, an impressive transformation is underway. With a rising number of biotechnology startups and major pharmaceutical companies setting up research facilities, the market in Asia-Pacific is emerging as a crucial hub for drug discovery. The region not only benefits from a large pool of scientific talent but also from cost-effective manufacturing and operational efficiencies. Rapid urbanization, increased healthcare funding, and ongoing initiatives to bolster scientific infrastructure are key drivers fueling the expansion of drug discovery activities in this geography. Additionally, local regulatory reforms and a focus on international collaboration have further solidified Asia-Pacific's role as a significant contributor to global drug innovation.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Pioneering Innovation in Drug Discovery

The landscape of drug discovery is significantly influenced by market leaders who continue to invest in breakthrough technologies and collaborative research. Renowned companies such as Abbott Laboratories, Inc., Amgen Inc., AstraZeneca PLC, Bayer Healthcare AG, and Bio-Rad Laboratories, Inc. have consistently driven innovation by integrating state-of-the-art methodologies in their drug development pipelines. Their commitment to excellence and research integrity has set benchmarks in the field.

Other notable players include bioMerieux SA, Bristol-Myers Squibb Company, Covaris, LLC, Curia Global, Inc., and Elucidata Corporation. These companies are known for their agile approaches to addressing therapeutic challenges and for leveraging multi-disciplinary technologies that bridge traditional and contemporary methods. Eurofins Advinus Private Limited, Evotec SE, F. Hoffmann-La Roche Ltd., and GE Healthcare Ltd. have also made significant contributions with robust research facilities and a strong emphasis on quality assurance.

Gilead Sciences, Inc. and Horiba, Ltd. have been trailblazers in driving targeted therapies and precision medicine, while Illumina, Inc. and IQVIA Inc. have supported the evolution of data-driven approaches in drug discovery. The expertise brought in by Luminex Corporation by DiaSorin Group and Merck & Co., Inc. further underscores the diverse capabilities required to navigate today's competitive market. Additionally, industry giants such as Novartis AG, Pfizer Inc., PIRAMAL PHARMA LIMITED, and Randox Laboratories Ltd. continue to redefine the standards of excellence.

The contributions of Revolution Medicines, Inc., Sanofi S.A., Sygnature Discovery Limited, Syngene International Limited, Thermo Fisher Scientific Inc., VWR International LLC, and WuXi AppTec Co., Ltd. are equally noteworthy. Each of these companies encapsulates the innovative spirit of the drug discovery sector, combining scientific research with commercial insights to develop therapies that address unmet medical needs. Their strategic initiatives not only enhance operational efficiencies but also ensure that cutting-edge technologies translate into tangible patient benefits.

The report delves into recent significant developments in the Drug Discovery Technologies Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Inc., Amgen Inc., AstraZeneca PLC, Bayer Healthcare AG, Bio-Rad Laboratories, Inc., bioMerieux SA, Bristol-Myers Squibb Company, Covaris, LLC, Curia Global, Inc., Elucidata Corporation, Eurofins Advinus Private Limited, Evotec SE, F. Hoffmann-La Roche Ltd., GE Healthcare Ltd., Gilead Sciences, Inc., Horiba, Ltd., Illumina, Inc., IQVIA Inc., Luminex Corporation by DiaSorin Group, Merck & Co., Inc., Novartis AG, Pfizer Inc., PIRAMAL PHARMA LIMITED, Randox Laboratories Ltd., Revolution Medicines, Inc., Sanofi S.A., Sygnature Discovery Limited, Syngene International Limited, Thermo FIsher Scientific Inc., VWR International LLC, and WuXi AppTec Co., Ltd.. Actionable Recommendations for Industry Leaders

Industry leaders are encouraged to adopt a multi-pronged approach when navigating the evolving landscape of drug discovery. First and foremost, integrating advanced computational models and high throughput screening should be prioritized. The efficiency gains from these technologies can translate into a swifter transition from ideation to clinical validation while minimizing costs and leveraging data to anticipate outcomes more reliably.

Investment in nanotechnology and structure-based design can substantially elevate the precision of therapeutic candidates. Leaders should consider bolstering R&D efforts by incorporating platforms that allow for molecular-level manipulation and precise targeting. It is prudent to foster cross-disciplinary collaboration between computational scientists, biologists, and chemists to ensure a holistic approach to drug development.

Furthermore, aligning strategies with pharmacogenomics will be instrumental in capturing the full potential of personalized medicine. By integrating genomic data into the decision-making process, companies can tailor treatments to patient-specific profiles, thereby improving efficacy and minimizing adverse effects. Strategic partnerships with academic institutions and biotech innovators can enhance access to critical genetic insights and cutting-edge research tools.

A strong emphasis on robust assay techniques-ranging from binding and biochemical assays to cell based and reporter gene assays-will further refine candidate screening and validation. Industry leaders should continuously update and diversify assay platforms to support the evaluation of compound efficacy comprehensively.

From an operational standpoint, leveraging strategic segmentation insights can streamline the allocation of resources. It is advisable to map investments across various segments including drug type, assay techniques, technology platforms, application areas, and end-user expectations. This methodical segmentation ensures that resources are deployed efficiently while addressing the unique demands of each market segment.

Lastly, a proactive stance on regulatory engagement and market-specific insights will enable companies to stay ahead of compliance challenges. Keeping abreast of regional regulations and leveraging local market dynamics can arm leaders with the competitive advantage necessary to capture growth in emerging markets. A clear strategy that prioritizes innovation, collaboration, and personalization will not only accelerate product development but also secure a sustainable competitive position in the industry.

Conclusion: Strategic Insights for Future Growth

In summary, the evolving landscape of drug discovery is marked by rapid technological advancements, strategic segmentation, and profound regional diversity. This dynamic environment requires industry stakeholders to adopt forward-thinking strategies and agile methodologies to remain competitive. The comprehensive integration of computational tools, advanced screening methods, and personalized medicine is reshaping how therapeutics are discovered and brought to market.

The progressive shift in assay techniques and the embrace of cutting-edge platforms such as nanotechnology and structure-based design have transformed the early stages of drug development. Moreover, a detailed segmentation based on drug type, assay techniques, technology platforms, applications, and end-user demographics offers a granular perspective on market dynamics, facilitating targeted investments and focused research initiatives.

Regional analysis further highlights that while the Americas lead with well-supported research ecosystems, Europe, Middle East & Africa offer a blend of traditional expertise and emerging innovation. The Asia-Pacific region's remarkable growth is underpinned by strategic regulatory reforms, cost efficiencies, and increasing collaborations. Each region presents its distinct set of opportunities and challenges, demanding tailored strategies from market participants.

The role of key industry players remains integral in driving innovation. The combined efforts of established pharmaceutical giants and nimble biotech companies are critical in pushing the boundaries of what is possible in drug discovery. Their continuous investments in R&D, adherence to stringent quality standards, and commitment to patient-centric solutions have laid the foundation for future breakthroughs.

Ultimately, the convergence of technology, segmentation insights, and regional market dynamics underscores the need for a deliberate, innovative, and collaborative approach. Firms that effectively harness these elements are better positioned to manage risks, capitalize on emergent opportunities, and achieve sustained growth in the highly competitive landscape of drug discovery.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of chronic diseases and unmet medical needs
    • 5.1.1.2. Growing use of small-molecular and biologics drugs to treat chronic and infectious disorders
    • 5.1.1.3. Rapid adoption of drug discovery technologies by CDMOs worldwide
  • 5.1.2. Restraints
    • 5.1.2.1. High overhead costs & concerns over high failure rate
  • 5.1.3. Opportunities
    • 5.1.3.1. Developing cutting-edge computational modeling and molecular simulation platforms
    • 5.1.3.2. Advancements in genomics research and high-throughput screening technologies
  • 5.1.4. Challenges
    • 5.1.4.1. Complex regulatory requirements and lengthy approval processes
• 5.2. Market Segmentation Analysis
  • 5.2.1. Drug Type: Rising significance of biologic drugs for treating autoimmune disorders and cancer
  • 5.2.2. End User: Expanding adoption of drug discovery technologies within academic institutions
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Drug Discovery Technologies Market, by Drug Type

• 6.1. Introduction
• 6.2. Biologic Drugs
• 6.3. Small-Molecule Drugs

7. Drug Discovery Technologies Market, by Assay Techniques

• 7.1. Introduction
• 7.2. Binding Assays
• 7.3. Biochemical Assays
• 7.4. Cell Based Assays
• 7.5. Reporter Gene Assays

8. Drug Discovery Technologies Market, by Technology Platforms

• 8.1. Introduction
• 8.2. Computational Modeling
• 8.3. High Throughput Screening
• 8.4. Nanotechnology
• 8.5. Pharmacogenomics
• 8.6. Structure Based Design

9. Drug Discovery Technologies Market, by Application

• 9.1. Introduction
• 9.2. Biomarker Discovery
• 9.3. Lead Discovery
• 9.4. Preclinical & Clinical Development
• 9.5. Target Identification & Validation
• 9.6. Toxicology Testing

10. Drug Discovery Technologies Market, by End User

• 10.1. Introduction
• 10.2. Academic Institutions
• 10.3. Biotechnology Firms
• 10.4. Pharmaceutical Companies

11. Americas Drug Discovery Technologies Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Drug Discovery Technologies Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Drug Discovery Technologies Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2024
• 14.2. FPNV Positioning Matrix, 2024
• 14.3. Competitive Scenario Analysis
  • 14.3.1. Novartis secures a full-paid license to leverage Housey Pharma's state-of-the-art drug discovery platform technologies
  • 14.3.2. Vividion Therapeutics acquires Tavros Therapeutics to enhance its genomic screening expertise and drug discovery
  • 14.3.3. AION Labs launched a new startup ProPhet, to enhance small molecule drug discovery
  • 14.3.4. Drug Development Technology player ArisGlobal Completes Acquisition of Amplexor Life Sciences.
  • 14.3.5. Luxna Announces Collaboration Agreement for Drug Discovery Research with Servier
  • 14.3.6. Iktos Raises €15.5M (USD 16.34 million) to Expand AI Drug Discovery Technologies
  • 14.3.7. Charles River Secures USD 50 Million Acquisition of Drug Discovery Tech Company.
  • 14.3.8. BioNTech to Acquire Ai Drug Discovery Start-Up Instadeep for £362m (USD 440.15 Million)
  • 14.3.9. CHARM Launches AI Drug Discovery Technology With USD 50 Million Series A Financing
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories, Inc.
• 2. Amgen Inc.
• 3. AstraZeneca PLC
• 4. Bayer Healthcare AG
• 5. Bio-Rad Laboratories, Inc.
• 6. bioMerieux SA
• 7. Bristol-Myers Squibb Company
• 8. Covaris, LLC
• 9. Curia Global, Inc.
• 10. Elucidata Corporation
• 11. Eurofins Advinus Private Limited
• 12. Evotec SE
• 13. F. Hoffmann-La Roche Ltd.
• 14. GE Healthcare Ltd.
• 15. Gilead Sciences, Inc.
• 16. Horiba, Ltd.
• 17. Illumina, Inc.
• 18. IQVIA Inc.
• 19. Luminex Corporation by DiaSorin Group
• 20. Merck & Co., Inc.
• 21. Novartis AG
• 22. Pfizer Inc.
• 23. PIRAMAL PHARMA LIMITED
• 24. Randox Laboratories Ltd.
• 25. Revolution Medicines, Inc.
• 26. Sanofi S.A.
• 27. Sygnature Discovery Limited
• 28. Syngene International Limited
• 29. Thermo FIsher Scientific Inc.
• 30. VWR International LLC
• 31. WuXi AppTec Co., Ltd.